Johanna Contreras
Advanced Heart Failure and Transplant Cardiology · New York, NYNPI 1528188190
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $327,640 of the $533,583 with a category attached, or 61.4%. It is spread thinly across 42 manufacturers, the largest accounting for just 14.7%. Reporting peaked in 2024 at $109,866 and has fallen 70.5% since, to $32,381 in 2025. Among advanced heart failure and transplant cardiology clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,317 payments — averaging $405.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim$79K
- Alnylam Pharmaceuticals Inc.$74K
- Abbott$54K
- AstraZeneca$44K
- Esperion Therapeutics, Inc.$34K
- Lexicon Pharmaceuticals, Inc.$32K
- plus $216K from 36 others
Across 243 payments — averaging $3488.30 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Livanova USA, Inc.$247K
- Boehringer Ingelheim International GmbH$211K
- AstraZeneca$106K
- E.r. Squibb & Sons, L.L.C.$68K
- Genentech, Inc.$59K
- Boehringer Ingelheim Pharma GmbH & Co.kg$51K
- plus $107K from 6 others
What the payments were for
- Consulting fees$112,09221%
- Speaking & faculty fees$327,64061%
- Travel & lodging$40,9788%
- Food & beverage$51,22110%
- Education$1,6520%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- JARDIANCE$88,029
- FARXIGA$41,670
- VERQUVO$36,228
- ONPATTRO$36,094
- NEXLETOL$33,828
- NEXLIZET$33,723
- Inpefa$31,317
- Mitra Clip system$24,945
- AMVUTTRA$24,865
- Barostim Neo System$23,514
- ENTRESTO$21,075
- HeartMate 3 Left Ventricular Dev$14,620
- Kerendia$14,184
- Attruby$11,769
- Adempas$6,240
- FUROSCIX$4,918
- MitraClip$3,651
- THORATEC HEARTMATE 3 LVAS IMPLANT KIT$3,047
- CAMZYOS$2,940
- VYNDAQEL$1,500
How this compares
$533,583 in reported general payments places this provider in the 95th percentile of 106 advanced heart failure and transplant cardiology providers in New York.
See all advanced heart failure and transplant cardiology providers in New York →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VyndamaxTafamidis | 31 | $1,057,699 |
| EntrestoSacubitril/Valsartan | 311 | $308,418 |
| JardianceEmpagliflozin | 312 | $265,059 |
| AdempasRiociguat | 12 | $157,092 |
| EliquisApixaban | 101 | $94,156 |
| OzempicSemaglutide | 70 | $86,884 |
| FarxigaDapagliflozin Propanediol | 87 | $76,168 |
| Repatha SureclickEvolocumab | 72 | $47,754 |
| InpefaSotagliflozin | 45 | $29,419 |
| MounjaroTirzepatide | 23 | $24,906 |
| XareltoRivaroxaban | 19 | $21,033 |
| LokelmaSodium Zirconium Cyclosilicate | 24 | $18,431 |
| KerendiaFinerenone | 24 | $16,390 |
| Praluent PenAlirocumab | 34 | $16,359 |
| VascepaIcosapent Ethyl | 38 | $15,864 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerVyndamax, Eliquis | $1,630 | $1,151,855132 claims |
| NovartisEntresto | $24,291 | $308,418311 claims |
| Boehringer IngelheimJardiance | $78,669 | $265,059312 claims |
| BayerAdempas, Kerendia | $20,905 | $173,48336 claims |
| AstraZenecaFarxiga, Lokelma | $44,266 | $94,599111 claims |
| Novo NordiskOzempic | $24,054 | $86,88470 claims |
| Lexicon Pharmaceuticals, Inc.Inpefa | $32,371 | $29,41945 claims |
| Lilly USA, LLCMounjaro | $24,971 | $24,90623 claims |
| Johnson & JohnsonXarelto | $53 | $21,03319 claims |
| MerckJanuvia | $28,751 | $12,64220 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 106 advanced heart failure and transplant cardiology providers in New York.
Other advanced heart failure and transplant cardiology in New York
- Sean PinneyNew York$305K
- Mathew MaurerNew York$249K
- Dor LotanNew York$158K
- Nir UrielNew York$125K
- Gabriel SayerNew York$95K
- Parag GoyalNew York$87K
- Alex ReyentovichNew York$49K
- Paolo ColomboNew York$44K
- Melana YuzefpolskayaNew York$44K
- Kelly AxsomNew York$33K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.